2021
TRYHARD, a randomized phase II trial (RTOG Foundation 3501) of concurrent accelerated radiation plus cisplatin (cis) with or without lapatinib (Lap) for stage III- IV Non-HPV head and neck carcinoma (HNC).
Wong S, Torres-Saavedra P, Saba N, Shenouda G, Bumpous J, Wallace R, Chung C, El-Naggar A, Gwede C, Burtness B, Tennant P, Dunlap N, Mell L, Spencer S, Stokes W, Yao M, Mitchell D, Harris J, Curran W, Le Q. TRYHARD, a randomized phase II trial (RTOG Foundation 3501) of concurrent accelerated radiation plus cisplatin (cis) with or without lapatinib (Lap) for stage III- IV Non-HPV head and neck carcinoma (HNC). Journal Of Clinical Oncology 2021, 39: 6014-6014. DOI: 10.1200/jco.2021.39.15_suppl.6014.Peer-Reviewed Original ResearchProgression-free survivalPhase II trialOverall survivalStage IIIII trialArm AGrade 3Treatment-related grade 3Randomized phase II trialFinal analysisEffects of chemoradiationBaseline patient characteristicsDays of therapyAdverse event ratesSurvival of patientsCycles of CDDPLog-rank testDual EGFRA vs BMucositis ratesRash ratesPFS ratePrimary endpointSecondary endpointsFrontline therapy
2010
Nonsurgical management of oropharyngeal, laryngeal, and hypopharyngeal cancer: The Fox Chase Cancer Center experience
Andrews G, Lango M, Cohen R, Feigenberg S, Burtness B, Mehra R, Ahmed S, Nicolaou N, Gaughan J, Ridge JA. Nonsurgical management of oropharyngeal, laryngeal, and hypopharyngeal cancer: The Fox Chase Cancer Center experience. Head & Neck 2010, 33: 1433-1440. PMID: 21928415, DOI: 10.1002/hed.21615.Peer-Reviewed Original ResearchMeSH KeywordsCancer Care FacilitiesCarcinoma, Squamous CellChemoradiotherapy, AdjuvantCohort StudiesDisease-Free SurvivalFemaleHumansHypopharyngeal NeoplasmsLaryngeal NeoplasmsMaleMiddle AgedNeoplasm Recurrence, LocalOropharyngeal NeoplasmsProportional Hazards ModelsRadiotherapy, ConformalRadiotherapy, Intensity-ModulatedRetrospective StudiesSalvage TherapySmokingConceptsSurvival of patientsNumber of patientsOropharyngeal cancerHypopharyngeal cancerT classificationLaryngeal cancerFox Chase Cancer Center experienceRetrospective single-institution cohort studyMultivariate analysisSingle-institution cohort studyRecurrent oropharyngeal cancerCancer Center experienceRecurrence-free survivalSubset of patientsLaryngeal cancer patientsDisease-related deathEarly T classificationHypopharyngeal cancer treatmentChemotherapy useCurative intentLocoregional controlCohort studyCurrent smokersOverall survivalSalvage surgery